Pharmacokinetics of oral ranitidine in Mexicans

G. Castaneda-Hernandez, F. J. Flores-Murrieta, V. Granados-Soto, A. Herrera-Abarca, J. Perez-Urizar, J. E. Herrera, E. Hong

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The pharmacokinetics of oral ranitidine were studied in 24 Mexican male healthy volunteers. Subjects received a tablet containing 150 mg of ranitidine (Azantac®, Glaxo de Mexico, Mexico City) after an overnight fast and blood samples were drawn at several times for a period of 24 h. Ranitidine concentration in plasma was measured by high performance liquid chromatography and pharmacokinetic parameters were determined by non-compartmental analysis. Ranitidine plasma concentration increased with time, reaching a maximum of (mean ± SEM) 484 ± 34 ng/ml in 2.7 ± 0.2 h. Plasma levels then decayed with a terminal half-life of 4.8 ± 0.3 h. The area under the plasma concentration against time curve was 2440 ± 126 ng.h/ml. Oral ranitidine pharmacokinetic parameters in Mexicans appeared to be similar to those previously reported for Caucasians.
Original languageAmerican English
Pages (from-to)349-352
Number of pages313
JournalArchives of Medical Research
StatePublished - 1 Oct 1996
Externally publishedYes

Fingerprint

Ranitidine
Pharmacokinetics
Mexico
Tablets
Half-Life
Healthy Volunteers
High Pressure Liquid Chromatography

Cite this

Castaneda-Hernandez, G., Flores-Murrieta, F. J., Granados-Soto, V., Herrera-Abarca, A., Perez-Urizar, J., Herrera, J. E., & Hong, E. (1996). Pharmacokinetics of oral ranitidine in Mexicans. Archives of Medical Research, 349-352.
Castaneda-Hernandez, G. ; Flores-Murrieta, F. J. ; Granados-Soto, V. ; Herrera-Abarca, A. ; Perez-Urizar, J. ; Herrera, J. E. ; Hong, E. / Pharmacokinetics of oral ranitidine in Mexicans. In: Archives of Medical Research. 1996 ; pp. 349-352.
@article{bb18ee720d704d438064e702e2198a06,
title = "Pharmacokinetics of oral ranitidine in Mexicans",
abstract = "The pharmacokinetics of oral ranitidine were studied in 24 Mexican male healthy volunteers. Subjects received a tablet containing 150 mg of ranitidine (Azantac{\circledR}, Glaxo de Mexico, Mexico City) after an overnight fast and blood samples were drawn at several times for a period of 24 h. Ranitidine concentration in plasma was measured by high performance liquid chromatography and pharmacokinetic parameters were determined by non-compartmental analysis. Ranitidine plasma concentration increased with time, reaching a maximum of (mean ± SEM) 484 ± 34 ng/ml in 2.7 ± 0.2 h. Plasma levels then decayed with a terminal half-life of 4.8 ± 0.3 h. The area under the plasma concentration against time curve was 2440 ± 126 ng.h/ml. Oral ranitidine pharmacokinetic parameters in Mexicans appeared to be similar to those previously reported for Caucasians.",
author = "G. Castaneda-Hernandez and Flores-Murrieta, {F. J.} and V. Granados-Soto and A. Herrera-Abarca and J. Perez-Urizar and Herrera, {J. E.} and E. Hong",
year = "1996",
month = "10",
day = "1",
language = "American English",
pages = "349--352",
journal = "Archives of Medical Research",
issn = "0188-0128",

}

Castaneda-Hernandez, G, Flores-Murrieta, FJ, Granados-Soto, V, Herrera-Abarca, A, Perez-Urizar, J, Herrera, JE & Hong, E 1996, 'Pharmacokinetics of oral ranitidine in Mexicans', Archives of Medical Research, pp. 349-352.

Pharmacokinetics of oral ranitidine in Mexicans. / Castaneda-Hernandez, G.; Flores-Murrieta, F. J.; Granados-Soto, V.; Herrera-Abarca, A.; Perez-Urizar, J.; Herrera, J. E.; Hong, E.

In: Archives of Medical Research, 01.10.1996, p. 349-352.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacokinetics of oral ranitidine in Mexicans

AU - Castaneda-Hernandez, G.

AU - Flores-Murrieta, F. J.

AU - Granados-Soto, V.

AU - Herrera-Abarca, A.

AU - Perez-Urizar, J.

AU - Herrera, J. E.

AU - Hong, E.

PY - 1996/10/1

Y1 - 1996/10/1

N2 - The pharmacokinetics of oral ranitidine were studied in 24 Mexican male healthy volunteers. Subjects received a tablet containing 150 mg of ranitidine (Azantac®, Glaxo de Mexico, Mexico City) after an overnight fast and blood samples were drawn at several times for a period of 24 h. Ranitidine concentration in plasma was measured by high performance liquid chromatography and pharmacokinetic parameters were determined by non-compartmental analysis. Ranitidine plasma concentration increased with time, reaching a maximum of (mean ± SEM) 484 ± 34 ng/ml in 2.7 ± 0.2 h. Plasma levels then decayed with a terminal half-life of 4.8 ± 0.3 h. The area under the plasma concentration against time curve was 2440 ± 126 ng.h/ml. Oral ranitidine pharmacokinetic parameters in Mexicans appeared to be similar to those previously reported for Caucasians.

AB - The pharmacokinetics of oral ranitidine were studied in 24 Mexican male healthy volunteers. Subjects received a tablet containing 150 mg of ranitidine (Azantac®, Glaxo de Mexico, Mexico City) after an overnight fast and blood samples were drawn at several times for a period of 24 h. Ranitidine concentration in plasma was measured by high performance liquid chromatography and pharmacokinetic parameters were determined by non-compartmental analysis. Ranitidine plasma concentration increased with time, reaching a maximum of (mean ± SEM) 484 ± 34 ng/ml in 2.7 ± 0.2 h. Plasma levels then decayed with a terminal half-life of 4.8 ± 0.3 h. The area under the plasma concentration against time curve was 2440 ± 126 ng.h/ml. Oral ranitidine pharmacokinetic parameters in Mexicans appeared to be similar to those previously reported for Caucasians.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0029791145&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=0029791145&origin=inward

M3 - Article

SP - 349

EP - 352

JO - Archives of Medical Research

JF - Archives of Medical Research

SN - 0188-0128

ER -

Castaneda-Hernandez G, Flores-Murrieta FJ, Granados-Soto V, Herrera-Abarca A, Perez-Urizar J, Herrera JE et al. Pharmacokinetics of oral ranitidine in Mexicans. Archives of Medical Research. 1996 Oct 1;349-352.